

Deborah O'Neil, Chief Executive & Scientific Officer, **NovaBiotics Ltd**

Deborah founded NovaBiotics in 2004. An immunologist by training with over fifteen year's experience in the field of antimicrobial peptides and anti-infectives research & development, Deborah studied at University College London and then worked in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen. It was here where, in order to fully develop the commercial potential of novel antimicrobial peptide therapies, NovaBiotics was formed. Deborah has since grown the business to a leading global biotechnology company with clinical-stage compounds and a robust and an exciting pipeline of anti-infective drug candidates. Deborah is editor of the European Biopharmaceutical Review, a member of the Scottish Life Sciences Advisory Board and sits on the Board of the Scottish Lifesciences Association.